Cargando…
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
BACKGROUND: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we charac...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020797/ https://www.ncbi.nlm.nih.gov/pubmed/36576430 http://dx.doi.org/10.1093/oncolo/oyac255 |
_version_ | 1784908345593823232 |
---|---|
author | Meza, Luis McDermott, David F Escudier, Bernard Hutson, Thomas E Porta, Camillo Verzoni, Elena Atkins, Michael B Kasturi, Vijay Pal, Sumanta K Rini, Brian |
author_facet | Meza, Luis McDermott, David F Escudier, Bernard Hutson, Thomas E Porta, Camillo Verzoni, Elena Atkins, Michael B Kasturi, Vijay Pal, Sumanta K Rini, Brian |
author_sort | Meza, Luis |
collection | PubMed |
description | BACKGROUND: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib. METHODS: We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety. RESULTS: Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib. CONCLUSIONS: Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib. |
format | Online Article Text |
id | pubmed-10020797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100207972023-03-18 Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 Meza, Luis McDermott, David F Escudier, Bernard Hutson, Thomas E Porta, Camillo Verzoni, Elena Atkins, Michael B Kasturi, Vijay Pal, Sumanta K Rini, Brian Oncologist Brief Communications BACKGROUND: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib. METHODS: We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety. RESULTS: Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib. CONCLUSIONS: Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib. Oxford University Press 2022-12-28 /pmc/articles/PMC10020797/ /pubmed/36576430 http://dx.doi.org/10.1093/oncolo/oyac255 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Brief Communications Meza, Luis McDermott, David F Escudier, Bernard Hutson, Thomas E Porta, Camillo Verzoni, Elena Atkins, Michael B Kasturi, Vijay Pal, Sumanta K Rini, Brian Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title | Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title_full | Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title_fullStr | Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title_full_unstemmed | Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title_short | Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 |
title_sort | tivozanib in patients with advanced renal cell carcinoma previously treated with axitinib: subgroup analysis from tivo-3 |
topic | Brief Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020797/ https://www.ncbi.nlm.nih.gov/pubmed/36576430 http://dx.doi.org/10.1093/oncolo/oyac255 |
work_keys_str_mv | AT mezaluis tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT mcdermottdavidf tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT escudierbernard tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT hutsonthomase tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT portacamillo tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT verzonielena tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT atkinsmichaelb tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT kasturivijay tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT palsumantak tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 AT rinibrian tivozanibinpatientswithadvancedrenalcellcarcinomapreviouslytreatedwithaxitinibsubgroupanalysisfromtivo3 |